胶质瘤是一种原发于中枢神经系统的恶性肿瘤。近年来，胶质瘤的治疗发展迅速，但胶质瘤患者的总体生存率并没有明显改善。由于血脑屏障和颅内肿瘤屏障的存在，许多体外治疗胶质瘤效果良好的药物无法准确输送到相应病灶。为了使抗肿瘤药物能够克服障碍并靶向神经胶质瘤，最近出现了纳米药物递送系统。令人欣慰的是，脂质体作为一种多功能纳米药物递送载体，具有与亲水性和疏水性药物相容、易于被各种靶向配体功能化、可生物降解、体内低免疫原性等特点，已成为解决胶质瘤用药难题的优质选择。 。因此，我们重点关注脂质体纳米药物递送系统，并总结其目前在胶质瘤中的研究进展。希望这篇综述能够为神经胶质瘤临床治疗的脂质体纳米材料的研发提供新思路。© 2024 Gan et al.

Glioma is a primary malignant tumor in the central nervous system. In recent years, the treatment of glioma has developed rapidly, but the overall survival of glioma patients has not significantly improved. Due to the presence of the blood-brain barrier and intracranial tumor barrier, many drugs with good effects to cure glioma in vitro cannot be accurately transported to the corresponding lesions. In order to enable anti-tumor drugs to overcome the barriers and target glioma, nanodrug delivery systems have emerged recently. It is gratifying that liposomes, as a multifunctional nanodrug delivery carrier, which can be compatible with hydrophilic and hydrophobic drugs, easily functionalized by various targeted ligands, biodegradable, and hypoimmunogenic in vivo, has become a quality choice to solve the intractable problem of glioma medication. Therefore, we focused on the liposome nanodrug delivery system, and summarized its current research progress in glioma. Hopefully, this review may provide new ideas for the research and development of liposome-based nanomaterials for the clinical treatment of glioma.© 2024 Gan et al.